Tumor Biology

, Volume 35, Issue 4, pp 3377–3383 | Cite as

VEGF-C expression is associated with the poor survival in gastric cancer tissue

Research Article

Abstract

Vascular endothelial growth factor-C (VEGF-C) is considered as a prime mediator of lymphangiogenesis and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF-C overexpression and the clinical outcome in patients with gastric cancer, but yielded conflicting results. Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF-C overexpression and survival of patients with gastric cancer. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of 13 studies that evaluated the correlation between VEGF-C overexpression and survival in patients with gastric cancer. Combined hazard ratios suggested that VEGF-C overexpression had an unfavorable impact on overall survival (OS) (hazard ratio (HR) = 1.38, 95 % confidence interval (CI) = 1.08–1.68), but not disease-free survival (DFS) (HR = 1.25, 95 % CI = 0.89–1.62) in patients with gastric cancer. No significant heterogeneity (P = 0.132) was observed among 11 studies for OS and among 5 studies for DFS (P = 0.105). VEGF-C overexpression indicates a poor prognosis for overall survival, but not disease-free survival in patients with gastric cancer.

Keywords

Vascular endothelial growth factor-C Gastric cancer Prognosis Meta-analysis 

Notes

Conflicts of interest

None.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Cancer J Clin. 2005;55:74–108.CrossRefGoogle Scholar
  2. 2.
    Amioka T, Kitadai Y, Tanaka S. Vascular endothelial growth factor C expression predicts lymph node metastasis of human gastric carcinoma invading the submucosa. Eur J Cancer. 2002;38:1413–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795–803.PubMedCrossRefGoogle Scholar
  5. 5.
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27.PubMedCrossRefGoogle Scholar
  6. 6.
    Karkkainen MJ, Alitalo K. Lymphatic endothelial regulation, lymphoedema, and lymph node metastasis. Semin Cell Dev Biol. 2002;13:9–18.PubMedCrossRefGoogle Scholar
  7. 7.
    Da MX, Wu Z, Tian HW. Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res. 2008;39:365–72.PubMedCrossRefGoogle Scholar
  8. 8.
    Cao R, Björndahl MA, Religa P, Clasper S, Garvin S, Galter D, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004;6:333–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Chang LK, Garcia-Cardeña G, Farnebo F, Fannon M, Chen EJ, Butterfield C, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A. 2004;101:11658–63.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Leong SP, Cady B, Jablons DM, Garcia-Aguilar J, Reintgen D, Jakub J, et al. Clinical patterns of metastasis. Cancer Metastasis Rev. 2006;25:221–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ. 2001;323(7306):224–8.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Zhan P, Qian Q, Yu LK. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis. 2013;5(1):40–7. doi:10.3978/j.issn.2072-1439.2013.01.02.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Zhan P, Qian Q, Wan B, Yan TD, Yu LK. Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis. Transl Cancer Res. 2013. doi:10.3978/j.issn.2218-676X.2013.02.08.Google Scholar
  14. 14.
    Zhan P, Wang Q, Qian Q, Yu LK. Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis. Transl Cancer Res. 2013;2(2):74–9. doi:10.3978/j.issn.2218-676X.2013.04.13.Google Scholar
  15. 15.
    Zhan P, Wang Q, Qian Q, Yu LK. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials. Chin Clin Oncol. 2013. doi:10.3978/j.issn.2304-3865.2013.01.02.Google Scholar
  16. 16.
    Zhan P, Qian Q, Yu LK. Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis. Hepatobiliary Surg Nutr. 2013. doi:10.3978/j.issn.2304-3881.2013.06.06.Google Scholar
  17. 17.
    Zhan P, Qian Q, Yu LK. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr. 2013. doi:10.3978/j.issn.2304-3881.2013.06.07.Google Scholar
  18. 18.
    Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Yusuf S, Peto R, Lewis J, et al. Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–71.PubMedCrossRefGoogle Scholar
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  21. 21.
    Egger M, Smith GD, Schneider M. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRefGoogle Scholar
  23. 23.
    Xie LX, Zhai TT, Yang LP, Yang E, Zhang XH, Chen JY, et al. Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma. Int J Exp Pathol. 2013;94(1):39–46.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Gou HF, Chen XC, Zhu J, Jiang M, Yang Y, Cao D, et al. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 2011;30:14.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Wang XL, Fang JP, Tang RY, Chen XM. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases. BMC Cancer. 2010;10:299.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Han FH, Li HM, Zheng DH, He YL, Zhan WH. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol. 2010;36(12):1172–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, et al. No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat. 2009;41(4):218–23.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Lee J, Kang WK, Park JO, Park SH, Park YS, Lim HY, et al. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. Apmis. 2009;117(8):598–606.PubMedCrossRefGoogle Scholar
  29. 29.
    Da MX, Wu XT, Wang J, Guo TK, Zhao ZG, Luo T, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 2008;39(1):92–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol. 2007;13(12):1794–8.PubMedGoogle Scholar
  31. 31.
    Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006;24(2):228–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Tsutsumi S, Kuwano H, Shimura T, Morinaga N, Mochiki E, Asao T. Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer. Hepatogastroenterology. 2005;52(62):629–32.PubMedGoogle Scholar
  33. 33.
    Takahashi A, Kono K, Itakura J, Amemiya H, Feng Tang R, Iizuka H, et al. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology. 2002;62(2):121–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Kimura H, Konishi K, Nukui T, Kaji M, Maeda K, Yabushita K, et al. Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol. 2001;76(1):31–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res. 1999;5(7):1823–9.PubMedGoogle Scholar
  36. 36.
    Parikh AA, Ellis LM. The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin N Am. 2004;18(5):951–71.CrossRefGoogle Scholar
  37. 37.
    Xie K, Wei D, Shi Q, Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 2004;15(5):297–324.PubMedCrossRefGoogle Scholar
  38. 38.
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci U S A. 1996;93(5):1988–92.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276(5317):1423–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012;39(10):9473–84.PubMedCrossRefGoogle Scholar
  42. 42.
    Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11(4):1434–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4(9):1094–103.PubMedCrossRefGoogle Scholar
  44. 44.
    Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94(12):1823–32.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100(9):1385–92.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12(17):5018–22.PubMedCrossRefGoogle Scholar
  47. 47.
    Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.PubMedCrossRefGoogle Scholar
  48. 48.
    Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:419–63.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of Oncology, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina
  2. 2.Department of Gastroenterology, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina
  3. 3.Department of General Surgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina

Personalised recommendations